Search
forLearn
5 / 801 resultslearn oligopeptide-71
learn Beta Polypeptide
learn unspecified lectican proteoglycans (nourkrin)
learn Pea peptides
Research
5 / 1000+ resultsresearch Allopregnanolone (AP) induces opioid inhibition of hypothalamo-pituitary-adrenal (HPA) axis responses to interleukin-1β (IL-1β) in pregnancy
Allopregnanolone and opioids together reduce stress hormone responses during pregnancy.
research Regulated Proenkephalin Expression in Human Skin and Cultured Skin Cells
Human skin cells produce proenkephalin, which changes with environmental factors and skin diseases.
research Central Opioid Inhibition of Neuroendocrine Stress Responses in Pregnancy in the Rat Is Induced by the Neurosteroid Allopregnanolone
In late pregnancy, allopregnanolone reduces stress responses in rats by affecting brain chemicals.
research Neuroendocrinology of the hair follicle: principles and clinical perspectives
Hair follicles are hormone-sensitive and involved in growth and other functions, with potential for new treatments, but more research is needed.
research International Journal of KIU
Genetics influence opioid addiction risk, diet affects COVID-19 severity, Aerva lanata may harm kidneys, some plants fight fungi and cancer, and nursing students need better contraceptive knowledge.
Community Join
5 / 1000+ resultscommunity Amplifica and AMP-303 clinical phase 1
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
community Published in Nature: Osteopontin, a protein involved in the growth of hair on moles could be the key to our troubles.
Osteopontin, a protein involved in hair growth on moles, may help with hair loss. However, it is also linked to Alzheimer's, cancer, and bone development, so caution is advised.
community The story of RU58841/PSK3841
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community Potential ( but not yet confirmed ) pp405 leak through korean media.
A peptide-based hair loss treatment, PP405, reportedly increased hair density by 62% in 90 days, but these claims are unverified and met with skepticism. Users compared PP405 to Minoxidil and Finasteride, expressing doubts about its effectiveness without more evidence.